SAB Biotherapeutics (SABS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing human polyclonal immunotherapeutic antibodies (hIgG) for immunology disorders, including type 1 diabetes (T1D) and other autoimmune diseases.

• Proprietary platform uses genetically engineered transchromosomic cattle to produce large quantities of disease-targeted hIgG without human plasma donors.

• Lead product candidate, SAB-142, is a first-in-class, human, multi-target anti-thymocyte globulin (ATG) for preventing or delaying T1D progression.

• Platform enables development of additional novel therapeutic candidates for complex immune-mediated disorders.

Financial performance and metrics

• Audited financial statements for 2023 and 2024 include a going concern warning, indicating substantial doubt about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be used for working capital and general corporate purposes.